Recent Developments in Tuberculosis Diagnosis, Treatment, and Control Strategies: A Global Overview

References

[1] World Health Organization. Global Tuberculosis Report 2022. Geneva: World Health Organization; 2022.

[2] Lönnroth, K., & Raviglione, M. (2016). The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Transactions of the Royal Society of Tropical Medicine and Hygiene, 110(3), 148–150. https://doi.org/10.1093/trstmh/trv108

[3] Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., Theron, G., Van Helden, P., Niemann, S., Merker, M., Dowdy, D., Van Rie, A., Siu, G. K. H., Pasipanodya, J. G., Rodrigues, C., . . . Warren, R. M. (2017). The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet Respiratory Medicine, 5(4), 291–360. https://doi.org/10.1016/s2213-2600(17)30079-6

[4] Mitnick, C. D., White, R. A., Lu, C., Rodriguez, C. A., Bayona, J., Becerra, M. C., Burgos, M., Centis, R., Cohen, T., Cox, H., D'Ambrosio, L., Danilovitz, M., Falzon, D., Gelmanova, I. Y., Gler, M. T., Grinsdale, J. A., Holtz, T. H., Keshavjee, S., Leimane, V., Menzies, D., … Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment (2016). Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. The European respiratory journal, 48(4), 1160–1170. https://doi.org/10.1183/13993003.00462-2016

[5] Dlamini, M. T., Lessells, R., Iketleng, T., & de Oliveira, T. (2019). Whole genome sequencing for drug-resistant tuberculosis management in South Africa: What gaps would this address and what are the challenges to implementation?. Journal of clinical tuberculosis and other mycobacterial diseases, 16, 100115. https://doi.org/10.1016/j.jctube.2019.100115

[6] Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., Peloquin, C. A., … Vernon, A. (2016). Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 63(7), e147–e195. https://doi.org/10.1093/cid/ciw376

[7] Rothstein D. M. (2016). Rifamycins, Alone and in Combination. Cold Spring Harbor perspectives in medicine, 6(7), a027011. https://doi.org/10.1101/cshperspect.a027011

[8] Diacon, A. H., Pym, A., Grobusch, M. P., De Los Rios, J. M., Gotuzzo, E., Vasilyeva, I., Leimane, V., Andries, K., Bakare, N., De Marez, T., Haxaire-Theeuwes, M., Lounis, N., Meyvisch, P., De Paepe, E., Van Heeswijk, R. P., & Dannemann, B. (2014). Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. New England Journal of Medicine, 371(8), 723–732. https://doi.org/10.1056/nejmoa1313865

[9] Pontali, E., Sotgiu, G., D'Ambrosio, L., Centis, R., & Migliori, G. B. (2016). Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. The European respiratory journal, 47(2), 394–402. https://doi.org/10.1183/13993003.01891-2015

[10] Skripconoka, V., Danilovits, M., Pehme, L., Tomson, T., Skenders, G., Kummik, T., Cirule, A., Leimane, V., Kurve, A., Levina, K., Geiter, L. J., Manissero, D., & Wells, C. D. (2013). Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. The European respiratory journal, 41(6), 1393–1400.

[11] Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., McHugh, T. D., Wills, G. H., Bateson, A., Hunt, R., Van Niekerk, C., Li, M., Olugbosi, M., Spigelman, M., & Nix-TB Trial Team (2020). Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. The New England journal of medicine, 382(10), 893–902. https://doi.org/10.1056/NEJMoa1901814

[12] Tiberi, S., Buchanan, R., Caminero, J. A., Centis, R., Arbex, M. A., Salazar, M., Potter, J., & Migliori, G. B. (2017). The challenge of the new tuberculosis drugs. Presse medicale (Paris, France: 1983), 46(2 Pt 2), e41–e51. https://doi.org/10.1016/j.lpm.2017.01.016

[13] WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539517/

[14] Trunz, B. B., Fine, P., & Dye, C. (2006). Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet (London, England), 367(9517), 1173–1180. https://doi.org/10.1016/S0140-6736(06)68507-3

[15] Van Der Meeren, O., Hatherill, M., Nduba, V., Wilkinson, R. J., Muyoyeta, M., Van Brakel, E., Ayles, H. M., Henostroza, G., Thienemann, F., Scriba, T. J., Diacon, A., Blatner, G. L., Demoitié, M. A., Tameris, M., Malahleha, M., Innes, J. C., Hellström, E., Martinson, N., Singh, T., Akite, E. J., … Tait, D. R. (2018). Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. The New England journal of medicine, 379(17), 1621–1634. https://doi.org/10.1056/NEJMoa1803484

[16] Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., Gilpin, C., Glaziou, P., Grzemska, M., Mirzayev, F., Nakatani, H., & Raviglione, M. (2015). WHO’s new End TB Strategy. The Lancet, 385(9979), 1799–1801. https://doi.org/10.1016/s0140-6736(15)60570-0

@article{1706810,
      author = {Dr Uzair Vohra, Dr Darpan Agrawal, Dr Shrey Chaudhari, Dr Huma Khan},
      title = {Recent Developments in Tuberculosis Diagnosis, Treatment, and Control Strategies: A Global Overview},
      journal = {Iconic Research And Engineering Journals},
      year = {2024},
      volume = {8},
      number = {6},
      pages = {880-884},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1706810.pdf},
      abstract = {Tuberculosis (TB) remains a significant global health challenge, particularly in resource-limited settings, where it disproportionately affects vulnerable populations. This review explores recent advancements in TB diagnosis and treatment, focusing on innovative strategies for both drug-sensitive and drug-resistant forms. A systematic search of relevant literature was conducted using databases such as PubMed, Scopus, and Web of Science, selecting studies published from 2015 to 2023 that report on TB diagnostic and treatment advancements. Advances in molecular diagnostics, such as the GeneXpert MTB/RIF, have revolutionized TB detection, enabling rapid and accurate identification of the disease and its drug-resistant strains. In terms of treatment, shorter and more effective drug regimens have emerged, enhancing adherence and improving patient outcomes. Notable developments include bedaquiline and delamanid for multidrug-resistant TB (MDR-TB), alongside the novel BPaL regimen, which combines pretomanid, bedaquiline, and linezolid, demonstrating high cure rates. Public health strategies, including active case finding and community-based treatment, are critical for curtailing transmission and addressing social determinants of health. This review also discusses ongoing research into vaccines, which are essential for preventing TB, particularly in high-risk populations. Despite the progress made, challenges remain in ensuring access to newer treatments in low-resource settings and addressing the rise of drug-resistant strains. This review provides a comprehensive overview of the current landscape in TB management and control, emphasizing improved treatment options and collaborative efforts necessary for enhanced patient outcomes and global TB eradication.},
      keywords = {Tuberculosis, Diagnosis, Treatment, Drug Resistance, Public Health Strategies},
      month = {December},
  }